Combination of statin/vitamin ID and metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of two randomized clinical trials.

被引：0
|
作者：
de Velasco, Guillermo
Lora, David
Carretero-Gonzalez, Alberto
Martin Soberon, Maria Cruz
Sepulveda Sanchez, Juan Manuel Manuel
Lorente, David
Castellano, Daniel E.
机构：
[1] Univ Hosp 12 Octubre, Dept Med Oncol, I 12, Madrid, Spain
[2] Hosp 12 Octubre, Madrid, Spain
[3] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[4] Hosp Univ 12 Octubre, Madrid, Spain
[5] Hosp Prov Castellon, Dept Med Oncol, Castellon De La Plana, Spain
[6] Hosp Univ 12 Octubre, Med Oncol Serv, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.6617
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6617
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Randomized phase II trial of abiraterone ± dasatinib for patients with metastatic castration-resistant prostate cancer (mCRPC).
    Dorff, Tanya B.
    Quinn, David I.
    Pinski, Jacek K.
    Goldkorn, Amir
    Sadeghi, Sarmad
    Tsao-Wei, Denice
    Groshen, Susan G.
    Kuhn, Peter
    Gross, Mitchell E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [32] Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium.
    Small, E. J.
    Beer, T. M.
    Weinberg, V. K.
    Higano, C. S.
    Nordquist, L. T.
    Rosenberg, J. E.
    Alumkal, J. J.
    Yu, E. Y.
    Sun, J.
    Lin, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] Overall survival of men with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line docetaxel-containing chemotherapy according to their participation (or not) in clinical trials.
    Goyal, Jatinder
    Huang, Peng
    Tyagi, Prachi
    Oh, Daniel
    Carducci, Michael Anthony
    Eisenberger, Mario A.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [34] Luminal and basal subtyping of metastatic castration-resistant prostate cancer (mCRPC) and its clinical implications.
    Kim, Won
    Small, Eric Jay
    Aggarwal, Rahul Raj
    Den, Robert Benjamin
    Lehrer, Jonathan
    Zhang, Li
    Youngren, Jack
    Goldstein, Theodore C.
    Alumkal, Joshi J.
    Gleave, Martin
    Rettig, Matthew
    Evans, Christopher P.
    Beer, Tomasz M.
    Reiter, Robert Evan
    Huang, Jiaoti
    Thomas, George V.
    Davicioni, Elai
    Ryan, Charles J.
    Spratt, Daniel Eidelberg
    Feng, Felix Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [35] Clinical activity of enzalutamide (Enza) pre- and post-docetaxel in teen with metastatic castration-resistant prostate cancer (mCRPC).
    Nadal, Rosa
    Zhang, Zhe
    Raheja, Hitesh
    Eisenherger, Mario A.
    Antonarakls, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] FATIGUE IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER TREATED WITH ENZALUTAMIDE: DATA FROM RANDOMIZED CLINICAL TRIALS
    Azad, Arun
    Saad, Fred
    Chowdhury, Simon
    Shore, Neal
    Higano, Celestia
    Fizazi, Karim
    Iversen, Peter
    Miller, Kurt
    Heidenreich, Axel
    Kim, Choung Soo
    Phung, De
    Krivoshik, Andrew
    Wang, Fong
    Tombal, Bertrand
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 41 - 41
  • [37] Impact of combined lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)
    Mak, B.
    Lin, H-M.
    Kwan, E. M.
    Fettke, H.
    Tran, B.
    Davis, I. D.
    Mahon, K. L.
    Stockler, M. R.
    Briscoe, K.
    Marx, G. M.
    Kohli, M.
    Tan, W.
    Huynh, K.
    Du, P.
    Yu, J.
    Jia, S.
    Joshua, A. M.
    Azad, A. A.
    Meikle, P. J.
    Horvath, L. G.
    ANNALS OF ONCOLOGY, 2021, 32 : S642 - S643
  • [38] Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials
    Massari, Francesco
    Modena, Alessandra
    Ciccarese, Chiara
    Pilotto, Sara
    Maines, Francesca
    Bracarda, Sergio
    Sperduti, Isabella
    Giannarelli, Diana
    Carlini, Paolo
    Santini, Daniele
    Tortora, Giampaolo
    Porta, Camillo
    Bria, Emilio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 98 : 254 - 263
  • [39] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Werner, Lillian
    Erlander, Mark G.
    Ridinger, Maya
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [40] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345